Nuwellis, Inc.
NUWENasdaqHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $8.3M | $8.7M | $8.9M | $8.5M | $7.9M | $7.4M |
| Operating income | −$11.1M | −$11.0M | −$17.6M | −$17.2M | −$19.5M | −$17.0M |
| Net income | −$17.5M | −$11.2M | −$20.2M | −$14.5M | −$19.6M | −$15.8M |
| Total assets | $6.1M | $9.9M | $9.8M | $24.7M | $30.4M | $20.0M |
| Total liabilities | $3.5M | $3.3M | $6.6M | $12.3M | $4.5M | $3.7M |
| Equity | $2.6M | $6.5M | $3.0M | $12.4M | $25.9M | $16.3M |
| EPS (diluted) | $-25.39 | $-353.30 | $-360.06 | $-83.55 | $-285.36 | $-10.67 |
| Shares out. | 4.4M | 6.8M | 1.2M | 10.5M | 6.5M | 20.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −134.3%
- Net margin
- −211.9%
- Return on equity
- −667.7%
- Return on assets
- −286.4%
- Return on capital (ROCE)
- −359.9%
- Liabilities / assets
- 57.0%
- Debt / equity
- 1.33×
- Book value / share
- $0.60
- Revenue growth (YoY)
- −5.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -177.65distress
- Accruals / assets
- −109.7%clean
- Beneish M-Score
- -7.65normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- Sabby Management, LlcPassive (13G)Jan 20, 2026
- Erb John LActivist (13D)Jun 16, 2025
- Intracoastal Capital, LlcPassive (13G)Jun 13, 2025
- Bigger Capital Fund L PPassive (13G)Jun 12, 2025
- S.H.N. Financial Investments Ltd.Passive (13G)Mar 18, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 35,355 | 1.0 | -49.6% |
| Apr 30, 2026 | 70,218 | 1.9 | +41.0% |
| Apr 15, 2026 | 49,796 | 1.3 | +57.0% |
| Mar 31, 2026 | 31,714 | 1.0 | +6.4% |
| Mar 13, 2026 | 29,815 | 1.0 | +6.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Shareholder voteApr 29, 2026
- Other material eventApr 24, 2026
- Director / officer changeMar 27, 2026
- Other material eventMar 17, 2026
- Results of operationsMar 10, 2026
- Director / officer change · Regulation FD disclosure · Other material eventFeb 26, 2026
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Director / officer change · Regulation FD disclosureJan 30, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.